Trial Profile
An Exploratory Phase 2, Randomized, Double-blind, Multicenter Study To Assess The Effects Of Tofacitinib (Cp-690,550) On Magnetic Resonance Imaging Endpoints, In Methotrexate Naive Subjects With Early Active Rheumatoid Arthritis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Tofacitinib (Primary) ; Methotrexate
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors Pfizer
- 05 Jun 2021 Results of a post hoc analysis assessing the impact of tofacitinib with or without methotrexate on MRI tenosynovitis and combined inflammation score in patients with early RA using semiquantitative and quantitative MRI outcomes presented at the 22nd Annual Congress of the European League Against Rheumatism
- 17 Jun 2017 Results assessing early changes in RAMRIQ as a predictor of radiographic progression, presented at the 18th Annual Congress of the European League Against Rheumatism
- 31 Jan 2017 Long term safety results (n=6194 data cut off 31 Mar 2015) of 2 phase I, 9 phase II, 6 phase III and 2 long term extension studies (NCT01262118, NCT01484561, NCT00147498, NCT00413660, NCT00550446, NCT00603512, NCT00687193, NCT01164579, NCT00976599, NCT01059864, NCT01359150, NCT00960440, NCT00847613, NCT00814307, NCT00856544, NCT00853385, NCT01039688, NCT00413699, NCT00661661) in adult patients with active Rheumatoid arthritis published in the Annals of the Rheumatic Diseases